疫情阶段校正分析显示乳腺癌患者新冠病毒固有脆弱性降低且疫苗对重症有显著保护作用
基于OnCovid注册研究,比较乳腺癌患者在疫苗接种前、Alpha-Delta和Omicron三个阶段的COVID-19发病率和死亡率,发现28天病死率无显著差异,但疾病严重程度随阶段改善;接种疫苗患者较未接种者28天病死率、住院、并发症及需特异性治疗和氧疗的风险均显著降低。
要点
- 乳腺癌患者三个疫情阶段的28天病死率分别为13.9%、12.2%和5.3%,无显著差异(P=0.182)。
- 未接种疫苗患者在Alpha-Delta和Omicron阶段的结果与疫苗接种前阶段相当。
- 接种疫苗患者较未接种者28天病死率降低(OR 0.19,95%CI 0.09-0.40)。
核心结论
- 在欧洲Omicron疫情期间,乳腺癌患者的COVID-19严重程度持续降低。
- 在该人群中,完成SARS-CoV-2疫苗全程接种是改善COVID-19发病和死亡的有力决定因素。
研究设计与样本
- 基于OnCovid注册研究(ClinicalTrials.gov标识NCT04393974),纳入613例符合条件的乳腺癌患者。
- 比较疫苗接种前(2020年2月27日至2020年11月30日)、Alpha-Delta(2020年12月1日至2021年12月14日)和Omicron(2021年12月15日至2022年1月31日)三个阶段的COVID-19发病率和死亡率。
- 采用逆概率治疗加权模型比较未接种疫苗与接种疫苗(双剂/加强针)患者,校正因素包括来源国、年龄、合并症数量、肿瘤分期及COVID-19诊断前1个月内接受全身抗癌治疗。
主要发现
- 613例患者中,激素受体阳性占60.1%(n=312),人表皮生长因子受体2阳性占25.2%(n=131),三阴性占14.6%(n=76)。
- 多数患者(61%,n=374)为局限/局部晚期疾病,中位年龄62岁(四分位距51-74岁),193例(31.5%)有≥2种合并症,69%(n=330)从不吸烟。
- 疫苗接种前、Alpha-Delta和Omicron阶段分别诊断392例(63.9%)、164例(26.8%)和57例(9.3%)。
- 三个阶段的28天病死率分别为13.9%、12.2%和5.3%,无显著差异(P=0.182);但COVID-19严重程度指标随时间显著改善。
- 未接种疫苗患者中,Alpha-Delta和Omicron阶段的结果与疫苗接种前阶段相当。
关键数值与推荐
- 接种疫苗患者较未接种者28天病死率改善(OR 0.19,95%CI 0.09-0.40)。
- 接种疫苗患者较未接种者住院风险降低(OR 0.28,95%CI 0.11-0.69)。
- 接种疫苗患者较未接种者COVID-19并发症风险降低(OR 0.16,95%CI 0.06-0.45)。
- 接种疫苗患者较未接种者需COVID-19特异性治疗的风险降低(OR 0.24,95%CI 0.09-0.63)。
- 接种疫苗患者较未接种者需氧疗的风险降低(OR 0.24,95%CI 0.09-0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS: We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. RESULTS: By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19-specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls. CONCLUSION: Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.
引用
- Tagliamento M, Gennari A, Lambertini M, et al. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. J Clin Oncol. 2023. PMID: 36720089. doi:10.1200/JCO.22.01667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。